Sudeep Pharma IPO Listing Today! GMP Jumps 20%- Check Listing Expectations & What To Do Post-Listing?
Sudeep Pharma IPO Listing Date: ₹895-crore Sudeep Pharma IPO (price band ₹563–₹593; lot 25) closed with robust demand and a healthy grey-market premium. Allotment was to be finalised on Nov 26, and the Sudeep Pharma IPO listing is scheduled today — investors are now focused on allotment status, GMP today and expected listing gains.

What were the key numbers for the Sudeep Pharma IPO?
| Stat | Figure |
|---|---|
| Issue size | ₹895 crore (Fresh ₹95cr + OFS ₹800cr). |
| Price band | ₹563 – ₹593 per share. |
| Lot size | 25 shares. |
| Overall subscription | 93.71× (applications: ~99.0 crore shares vs 1.06 crore on offer). |
| Category break-up (approx.) | QIB: 213.08×, NII: 116.71×, RII: 15.63×. |
| Allotment date | Nov 26, 2025 (as reported). |
| Tentative listing date | Nov 28, 2025 (NSE/BSE). |
What is the Sudeep Pharma IPO GMP today — how strong is the grey market?
Grey Market Premium (GMP) showed healthy activity ahead of listing; most market trackers put the GMP in the range ₹80–₹120 in the days before allotment, with recent mainstream reporting noting GMP around ~20 of the upper band.
This implies strong secondary-market interest but remember GMP is informal and can swing quickly.
What Sudeep Pharma IPO listing price and listing gain should investors expect?
Using the commonly quoted GMP (~₹121) against the upper band (₹593), a simple expectation would be a Sudeep Pharma IPO listing near ₹714/share (₹593 + ₹121) — i.e., a listing gain ≈ of ₹110–₹120 per share (~20%) if the GMP materialises into the listing price.
This is an expectation (not a guarantee) and depends on market mood at open.
How can I check my allotment — exactly which steps should I follow?
You can check your Sudeep Pharma IPO allotment status through:
- Visit the registrar (MUFG Intime India) allotment page — enter PAN or application no. and check. Click Here.
- Check BSE/NSE application status pages using PAN.
- Broker / Demat account — many brokers show allotment in IPO section once basis of allotment is uploaded.
What are expert views — should you hold, list-flip or avoid?
Market commentators are broadly positive on Sudeep Pharma’s long-term fundamentals — strong FY25 metrics and a niche presence in excipients/speciality ingredients — but caution on valuation for short-term traders: some analysts point to an aggressive P/E and advise long-term holding rather than flip-only bets.
Brokers highlighted strong demand from institutions and healthy GMP as supportive for a good listing.
What must an investor do post-listing?
- If allotted and you plan to hold — check fundamentals and 6–12 month outlook; set stop-loss and target levels.
- If you don’t get allotment — don’t chase the stock at lofty premiums; consider valuation before buying on listing.
- If listing gains appear — decide whether to book partial profits (tax and portfolio considerations).
- Monitor liquidity — OFS heavy issues can have volatile first-day trading; trade with caution.
Conclusion
The robust demand and a healthy grey-market premium are pointing to a probable upbeat Sudeep Pharma IPO listing. Investors should verify individual allotment status, weigh listing opportunities against valuation, and align any buy/flip decision with their risk profile.
Remember: GMP is indicative, not guaranteed, and fundamentals matter after the first trading day.
FAQs on Sudeep Pharma IPO Listing
1. When will Sudeep Pharma IPO allotment be finalised?
The Sudeep Pharma IPO allotment will be finalised today, November 26.
2. What was the overall Sudeep Pharma IPO subscription?
The Sudeep Pharma IPO subscribed 93.71x overall.
3. What is the Sudeep Pharma IPO GMP today?
The Sudeep Pharma IPO GMP today surges to 20% of upper price band.
4. What is the Sudeep Pharma IPO listing date?
The Sudeep Pharma IPO listign date is November 28.
5. When will shares credit to Demat if allotted?
The share credit is expected on or before the listing date.
Click Here to know more market & IPO related news and updates.
Disclaimer: The views and investment insights provided here are based on publicly available information and do not constitute financial advice. Readers are advised to conduct their own research or consult certified financial experts before making investment decisions.



